Lineage Cell Therapeutics (LCTX)
(Delayed Data from AMEX)
$0.97 USD
-0.05 (-4.65%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $0.97 0.00 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
Lineage Cell Therapeutics, Inc. [LCTX]
Reports for Purchase
Showing records 41 - 60 ( 97 total )
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: An Early Christmas as Roche Genentech Opts In for $50M Upfront for the OpGen/Dry AMD
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Christmas Comes Early for OpRegen Data as Genentech Steps Up
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Fantastic Four: Reports a Fourth Case of Retinal Tissue Restoration with OpRegen
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Seeing Is Believing; Fourth Example of a Never Been Seen Before; FDA Meeting Around the Corner
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Structural Improvements Merging Nicely with BCVA Improvements with OpRegen Treatment
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Results; We See Data Driving Productive Regulatory Discussions
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Impressive OpRegen Durability Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Promising Interim Results Continue For OpRegen With Latest Clinical Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Generate Groundbreaking Data, Look to FDA for Feedback; Sounds Pretty Simple to Us
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
OpRegen Continues Its Impressive Run Ahead of FDA Meeting in 4Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
OPC1 Gets Clarity on Path Forward With FDA Feedback; Phase 1 Device-Validating Study in 4Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Seeing the Opportunity - Stock Jumps on Data
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Three Points Make a Straight Line; OpRegen Continues to Solidify Restoration Thesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; Busy Cell Therapy Beavers; OpRegen Leading the Differentiated Charge
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Lineage Cell Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
OpRegen Continues to Impress at ARVO; FDA Talks Planned for 3Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J